BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Ischemia, Stem cell, Biofuel, Lovastatin, rs2230926, GATA1, Angiogenesis)
Bookmark Forward

QuickView for protozoan vaccines (compound)


Genetic Markers

Most Correlated Genes

  1. CXCL8
  2. SERPING1
  3. CXCL10
  4. TFEC
  5. GBP1P1
Explore Genetic Markers Results

Pathway Enrichment

Most Correlated Biogroups

  1. NUYTTEN_EZH2_TARGETS_UP
  2. GSE13485_DAY1_VS_DAY7_YF17D_VACCINE_PBMC_DN
  3. GSE18791_CTRL_VS_NEWCASTLE_VIRUS_DC_6H_DN
  4. PILON_KLF1_TARGETS_DN
  5. GSE13485_DAY1_VS_DAY3_YF17D_VACCINE_PBMC_DN
Explore Pathway Enrichment Results

Curated Studies

Most Correlated Studies

  1. PBMC expression data from a malaria vaccine trial
  2. Whole blood of subjects with ChAd63-KH leishmaniasis vaccination
  3. Blood of subjects before and after Plasmodium falciparum sporozoite vaccination
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Toxoplasma gondii-Current drugs and future vaccines against an underestimated protozoan infection].
  2. A state-of-the-art methodology for high-throughput in silico vaccine discovery against protozoan par…
  3. Vaccination with parasite-specific TcTASV proteins combined with recombinant baculovirus as a delive…
  4. Memory-like NK Cells Are a Critical Component of Vaccine-Induced Immunity to Trypanosoma cruzi Infec…
  5. Protective efficacy of the oral vaccine Tc24:Co1 produced in Schizochytrium sp. against Trypanosoma …
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Parasitism & COVID19 Vaccines: New Challenge.
  2. LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine
  3. EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria
  4. Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin
  5. Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleuk…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.